Abstract

Neutrophils are frequently studied in mouse models, but the extent to which findings translate to humans remains poorly defined. In an integrative analysis of 11 mouse and 13 human datasets, we find a strong correlation of neutrophil gene expression across species. In inflammation, neutrophils display substantial transcriptional diversity but share a core inflammation program. This program includes genes encoding IL-1 family members, CD14, IL-4R, CD69, and PD-L1. Chromatin accessibility of core inflammation genes increases in blood compared to bone marrow and further in tissue. Transcription factor enrichment analysis implicates members of the NF-κB family and AP-1 complex as important drivers, and HoxB8 neutrophils with JunB knockout show a reduced expression of core inflammation genes in resting and activated cells. In independent single-cell validation data, neutrophil activation by type I or type II interferon, G-CSF, and E. coli leads to upregulation in core inflammation genes. In COVID-19 patients, higher expression of core inflammation genes in neutrophils is associated with more severe disease. In vitro treatment with GM-CSF, LPS, and type II interferon induces surface protein upregulation of core inflammation members. Together, we demonstrate transcriptional conservation in neutrophils in homeostasis and identify a core inflammation program shared across heterogeneous inflammatory conditions.

Difficulties can be encountered when translating research between cells from animals and humans because of gene expression differences. Here the authors perform an integrative transcriptomic analysis from human and mouse neutrophils and identify a core inflammation program shared across inflamed contexts.

Details

Title
Human and mouse neutrophils share core transcriptional programs in both homeostatic and inflamed contexts
Author
Hackert, Nicolaj S. 1   VIAFID ORCID Logo  ; Radtke, Felix A. 2   VIAFID ORCID Logo  ; Exner, Tarik 3 ; Lorenz, Hanns-Martin 4 ; Müller-Tidow, Carsten 5   VIAFID ORCID Logo  ; Nigrovic, Peter A. 6   VIAFID ORCID Logo  ; Wabnitz, Guido 7   VIAFID ORCID Logo  ; Grieshaber-Bouyer, Ricardo 8 

 Heidelberg University Hospital, Division of Rheumatology, Department of Medicine V, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); Heidelberg University Hospital, Institute for Immunology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); Harvard Medical School, Division of Immunology, Boston Children’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) 
 Heidelberg University Hospital, Division of Rheumatology, Department of Medicine V, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); Heidelberg University Hospital, Institute for Immunology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); Brigham and Women’s Hospital, Harvard Medical School, Division of Rheumatology, Inflammation and Immunity, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); University of Oxford, MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Oxford Centre for Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 Heidelberg University Hospital, Division of Rheumatology, Department of Medicine V, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); Heidelberg University Hospital, Institute for Immunology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908) 
 Heidelberg University Hospital, Division of Rheumatology, Department of Medicine V, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908) 
 Heidelberg University Hospital, Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); University of Heidelberg, Molecular Medicine Partnership Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373) 
 Harvard Medical School, Division of Immunology, Boston Children’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Harvard Medical School, Division of Rheumatology, Inflammation and Immunity, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Heidelberg University Hospital, Institute for Immunology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908) 
 Heidelberg University Hospital, Division of Rheumatology, Department of Medicine V, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); Heidelberg University Hospital, Institute for Immunology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908); University of Heidelberg, Molecular Medicine Partnership Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373); Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Deutsches Zentrum für Immuntherapie (DZI), Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311); Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany (GRID:grid.411668.c) (ISNI:0000 0000 9935 6525) 
Pages
8133
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2899555621
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.